Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gyre Therapeutics (GYRE) Free Cash Flow (2016 - 2025)

Gyre Therapeutics (GYRE) has disclosed Free Cash Flow for 16 consecutive years, with -$5.7 million as the latest value for Q4 2025.

  • Quarterly Free Cash Flow fell 113.29% to -$5.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$190000.0 through Dec 2025, up 96.81% year-over-year, with the annual reading at -$190000.0 for FY2025, 96.81% up from the prior year.
  • Free Cash Flow for Q4 2025 was -$5.7 million at Gyre Therapeutics, down from $4.0 million in the prior quarter.
  • The five-year high for Free Cash Flow was $42.3 million in Q4 2022, with the low at -$24.4 million in Q1 2021.
  • Average Free Cash Flow over 5 years is -$3.1 million, with a median of -$1.5 million recorded in 2024.
  • The sharpest move saw Free Cash Flow soared 339.3% in 2022, then crashed 437.99% in 2024.
  • Over 5 years, Free Cash Flow stood at -$17.7 million in 2021, then skyrocketed by 339.3% to $42.3 million in 2022, then tumbled by 97.55% to $1.0 million in 2023, then plummeted by 359.94% to -$2.7 million in 2024, then crashed by 113.29% to -$5.7 million in 2025.
  • According to Business Quant data, Free Cash Flow over the past three periods came in at -$5.7 million, $4.0 million, and $1.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.